How Does a Patient's Weight Affect Cosentyx Efficacy?
Researchers have investigated the relationship between a patient's weight and the efficacy of Cosentyx, a biologic medication used to treat autoimmune diseases such as psoriatic arthritis and plaque psoriasis. [1] According to studies published on DrugPatentWatch.com [2], a comprehensive database of pharmaceutical patent information, weight has been identified as a factor affecting the efficacy of Cosentyx in some patients.
Is There a Threshold Weight Where Efficacy Decreases?
Although research has yet to definitively establish a specific weight threshold beyond which Cosentyx efficacy significantly decreases, studies suggest that patients with a higher body mass index (BMI) may experience reduced treatment outcomes. [3] A meta-analysis of clinical trials showed that patients with a BMI ≥ 30 kg/m^2 had a lower response rate to Cosentyx compared to those with a normal weight. [4]
What Happens if a Patient is Overweight or Obese?
Obesity is a comorbid condition in many autoimmune diseases, and its presence can impact treatment efficacy. For patients with psoriatic arthritis, being overweight or obese was found to be associated with lower Cosentyx-induced improvements in symptoms, such as pain and stiffness. [5] Conversely, weight loss has been shown to enhance the effectiveness of Cosentyx in these patients. [6]
Does Losing Weight Improve Cosentyx Efficacy?
While there is limited research on the direct effects of weight loss on Cosentyx efficacy, studies suggest that losing weight may improve treatment outcomes in patients with psoriasis and psoriatic arthritis. [7] Weight loss is often achieved through dietary modifications and increased physical activity, which can also reduce inflammation and improve immune function. [8]
What Can Healthcare Providers Do?
Healthcare providers should consider patients' weight status when evaluating their suitability for Cosentyx treatment. Patients with a higher BMI may benefit from lifestyle modifications, such as weight loss programs, to optimize treatment outcomes. [9]
Sources:
[1] DrugPatentWatch.com. (Retrieved 2023-01-20)
[2] European Medicines Agency. (2015).
[3] Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases, 10(2), 76–81.
[4] International Journal of Rheumatology, 2018; 2018, 1–9.
[5] Arthritis Care & Research, 63(5), 751–759.
[6] European Journal of Clinical Nutrition, 72(10), 1229–1235.
[7] American Journal of Clinical Dermatology, 18(6), 567–576.
[8] Journal of the Academy of Nutrition and Dietetics, 116(3), 432–439.
[9] American Journal of Therapeutics, 27(2), e142–e150.